FDA Approves Dyloject for Mild, Severe Pain

Disease-Modifying Relapsing MS Treatments
Disease-Modifying Relapsing MS Treatments
Dyloject can be infused in a short amount of time compared to other intravenous analgesics.

The US Food and Drug Administration (FDA) has approved diclofenac sodium injection (Dyloject, Hospira Inc), a proprietary nonsteroidal anti-inflammatory drug (NSAID) for the treatment of mild to moderate pain, and for the management of moderate to severe pain alone or in combination with opioids.

“While not a replacement for opioids, Dyloject is another injectable therapy option that can be administered more conveniently in a small volume intravenous bolus over 15 seconds as opposed to other injectable non-opioid analgesics that are formulated in large volumes or require dilution prior to administration and typically require an infusion of 15 to 30 minutes to administer the full dose,” notes a statement from the company announcing the FDA approval.

READ FULL ARTICLE Curated publisher From Med Scape